0.441.241853956839279860001427570--12-312022Q1false953889538817831875185975220.3330001427570rsls:NewWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-07-160001427570rsls:NewWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-07-160001427570rsls:NewWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-07-160001427570rsls:NewWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2021-07-160001427570rsls:ObalonTherapeuticsInc.Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-07-150001427570rsls:ObalonTherapeuticsInc.Memberus-gaap:MeasurementInputPriceVolatilityMember2021-07-150001427570rsls:ObalonTherapeuticsInc.Memberus-gaap:MeasurementInputExpectedDividendRateMember2021-07-150001427570rsls:NewUnregisteredWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-06-280001427570rsls:NewUnregisteredWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-06-280001427570rsls:NewUnregisteredWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-06-280001427570rsls:NewUnregisteredWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2021-06-280001427570rsls:SeriesGWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-01-190001427570rsls:SeriesGWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-01-190001427570rsls:SeriesGWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-01-190001427570rsls:SeriesGWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2021-01-190001427570us-gaap:CommonStockMember2022-01-012022-03-310001427570us-gaap:CommonStockMemberrsls:PrivatePlacements2019Member2021-06-212021-06-2100014275702021-06-152021-06-150001427570us-gaap:RetainedEarningsMember2022-03-310001427570us-gaap:AdditionalPaidInCapitalMember2022-03-310001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001427570us-gaap:RetainedEarningsMember2021-12-310001427570us-gaap:AdditionalPaidInCapitalMember2021-12-310001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001427570us-gaap:RetainedEarningsMember2021-03-310001427570us-gaap:AdditionalPaidInCapitalMember2021-03-310001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001427570us-gaap:RetainedEarningsMember2020-12-310001427570us-gaap:AdditionalPaidInCapitalMember2020-12-310001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001427570rsls:SeriesCConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-03-310001427570us-gaap:CommonStockMember2022-03-310001427570rsls:SeriesCConvertiblePreferredStockMemberus-gaap:PreferredStockMember2021-12-310001427570us-gaap:CommonStockMember2021-12-310001427570rsls:SeriesCConvertiblePreferredStockMemberus-gaap:PreferredStockMember2021-03-310001427570rsls:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2021-03-310001427570us-gaap:CommonStockMember2021-03-310001427570rsls:SeriesCConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-12-310001427570rsls:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-12-310001427570us-gaap:CommonStockMember2020-12-310001427570us-gaap:EmployeeStockOptionMember2021-12-310001427570us-gaap:RestrictedStockUnitsRSUMember2021-12-310001427570us-gaap:NonUsMember2022-01-012022-03-310001427570srt:EuropeMember2022-01-012022-03-310001427570rsls:ReshapeVestAndDiabetesBlocStimNeuromodulationProductsMember2022-01-012022-03-310001427570country:US2022-01-012022-03-310001427570country:AU2022-01-012022-03-310001427570us-gaap:NonUsMember2021-01-012021-03-310001427570srt:EuropeMember2021-01-012021-03-310001427570rsls:ReshapeVestAndDiabetesBlocStimNeuromodulationProductsMember2021-01-012021-03-310001427570country:US2021-01-012021-03-310001427570country:AU2021-01-012021-03-310001427570rsls:SeriesBConvertiblePreferredStockMember2022-03-310001427570rsls:SeriesBConvertiblePreferredStockMember2021-12-310001427570rsls:CreditAgreementMember2021-06-282021-06-280001427570rsls:PaycheckProtectionProgramLoanMember2020-04-242020-04-240001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001427570us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001427570us-gaap:RetainedEarningsMember2022-01-012022-03-310001427570us-gaap:RetainedEarningsMember2021-01-012021-03-3100014275702021-08-062021-08-060001427570rsls:SanClementeOfficeAndWarehouseSpaceMember2022-03-310001427570rsls:CarlsbadOfficeAndWarehouseSpaceMember2022-03-310001427570rsls:CreditAgreementMember2021-01-192021-01-190001427570rsls:PaycheckProtectionProgramLoanMember2021-01-012021-03-310001427570srt:MinimumMember2022-01-012022-03-310001427570srt:MaximumMember2022-01-012022-03-310001427570us-gaap:EmployeeStockOptionMember2022-03-310001427570us-gaap:RestrictedStockUnitsRSUMember2022-03-310001427570us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001427570rsls:CreditAgreementMember2021-03-300001427570us-gaap:SecuredDebtMemberus-gaap:MeasurementInputDiscountRateMember2022-03-310001427570rsls:CreditAgreementMember2021-01-012021-03-310001427570srt:MaximumMemberrsls:NewWarrantsMember2021-07-160001427570rsls:SeriesGWarrantsMemberrsls:CreditAgreementMember2021-01-190001427570rsls:ExchangeWarrantsMember2021-07-160001427570srt:MinimumMemberrsls:ObalonTherapeuticsInc.Member2021-07-150001427570srt:MaximumMemberrsls:ObalonTherapeuticsInc.Member2021-07-150001427570rsls:SeriesGWarrantsIssuedMarch252020Member2021-06-280001427570rsls:SeriesGWarrantsIssuedJanuary212021Member2021-06-280001427570rsls:SeriesGWarrantsIssuedDecember172020Member2021-06-280001427570rsls:SeriesEWarrantsMember2021-06-280001427570rsls:SeriesGWarrantsIssuedMarch252020Member2021-06-270001427570rsls:SeriesGWarrantsIssuedJanuary212021Member2021-06-270001427570rsls:SeriesGWarrantsIssuedDecember172020Member2021-06-270001427570rsls:SeriesEWarrantsMember2021-06-2700014275702020-12-310001427570rsls:ObalonTherapeuticsInc.Member2022-01-012022-03-310001427570rsls:ObalonTherapeuticsInc.Member2021-01-012021-03-310001427570us-gaap:WarrantMember2022-01-012022-03-310001427570us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001427570us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001427570us-gaap:ConvertiblePreferredStockMember2022-01-012022-03-310001427570us-gaap:WarrantMember2021-01-012021-03-310001427570us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001427570us-gaap:ConvertiblePreferredStockMember2021-01-012021-03-310001427570us-gaap:SellingAndMarketingExpenseMember2022-01-012022-03-310001427570us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001427570us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001427570us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001427570us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001427570us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001427570rsls:ObalonTherapeuticsInc.Memberus-gaap:DevelopedTechnologyRightsMember2022-01-012022-03-310001427570rsls:SeriesCConvertiblePreferredStockMember2022-03-310001427570rsls:SeriesCConvertiblePreferredStockMember2021-12-310001427570rsls:ObalonTherapeuticsInc.Member2021-09-300001427570rsls:SeriesGWarrantsMember2021-01-192021-01-190001427570rsls:NewUnregisteredWarrantsMember2021-06-282021-06-280001427570rsls:ClassOfWarrantInvestorsIssuedJune2021Member2021-06-282021-06-280001427570rsls:PrivatePlacements2019Member2021-06-212021-06-210001427570us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001427570rsls:ClassOfWarrantInvestorsIssuedJune2021Memberrsls:CreditAgreementMember2021-06-282021-06-2800014275702021-12-3100014275702022-03-3100014275702021-03-3100014275702021-06-212021-06-2100014275702021-06-182021-06-1800014275702021-08-182021-08-180001427570rsls:ObalonTherapeuticsInc.Member2021-07-012021-09-300001427570rsls:ObalonTherapeuticsInc.Memberus-gaap:DevelopedTechnologyRightsMemberus-gaap:MeasurementInputDiscountRateMember2022-03-3100014275702021-01-012021-03-310001427570rsls:CreditAgreementMember2021-01-190001427570us-gaap:RestrictedStockMember2021-08-112021-08-110001427570rsls:NewWarrantsMember2021-07-160001427570rsls:ObalonTherapeuticsInc.Member2021-07-1500014275702021-07-160001427570rsls:NewUnregisteredWarrantsMember2021-06-280001427570rsls:ObalonTherapeuticsInc.Member2021-06-152021-06-150001427570rsls:ObalonTherapeuticsInc.Member2021-06-1500014275702022-05-1900014275702022-01-012022-03-31xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesrsls:individualrsls:itemrsls:Y

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

Commission file number: 1-37897

RESHAPE LIFESCIENCES INC.

(Exact name of registrant as specified in its charter)

Delaware

26-1828101

(State or other jurisdiction
of incorporation or organization)

(IRS Employer
Identification No.)

1001 Calle Amanecer, San Clemente, California 92673
(Address of principal executive offices, including zip code)

(949) 429-6680
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

    

Trading Symbol

Name of Each Exchange on which Registered

Common stock, $0.001 par value per share

RSLS

The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Accelerated Filer

Non-accelerated Filer

  

Smaller Reporting Company

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of May 19, 2022, 18,693,219 shares of the registrant’s Common Stock were outstanding.

Table of Contents

INDEX

PART I – FINANCIAL INFORMATION

Item 1.

Condensed Consolidated Financial Statements (unaudited)

3

Condensed Consolidated Balance Sheets at March 31, 2022 and December 31, 2021

3

Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021

4

Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2022 and 2021

5

Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2022 and 2021

6

Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021

7

Notes to Condensed Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

26

Item 4.

Controls and Procedures

26

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

26

Item 1A.

Risk Factors

27

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

27

Item 3.

Defaults Upon Senior Securities

27

Item 4.

Mine Safety Disclosures

27

Item 5.

Other Information

27

Item 6.

Exhibits

28

SIGNATURES

29

2

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1.        CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Balance Sheets

(unaudited)

(dollars in thousands, except per share amounts)

March 31, 

December 31, 

    

2022

    

2021

ASSETS

Current assets:

Cash and cash equivalents

$

15,410

 

$

22,765

Restricted cash

50

50

Accounts and other receivables (net of allowance for doubtful accounts of $1,087 and $1,172 respectively)

 

2,410

 

 

2,815

Inventory

 

3,998

 

 

3,003

Prepaid expenses and other current assets

 

1,759

 

 

1,622

Total current assets

 

23,627

 

 

30,255

Property and equipment, net

 

1,371

 

 

1,454

Operating lease right-of-use assets

524

266

Other intangible assets, net

20,371

20,827

Other assets

 

1,377

 

 

1,456

Total assets

$

47,270

 

$

54,258

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

3,598

 

$

3,468

Accrued and other liabilities

 

3,463

 

 

3,169

Warranty liability, current

649

415

Operating lease liabilities, current

441

279

Total current liabilities

 

8,151

 

 

7,331

Operating lease liabilities, noncurrent

86

Warranty liability, noncurrent

41

300

Deferred income taxes

367

555

Total liabilities

8,645

 

8,186

Commitments and contingencies

Stockholders’ equity:

Preferred stock, 10,000,000 shares authorized:

Series C convertible preferred stock, $0.001 par value; 95,388 shares issued and outstanding at March 31, 2022 and December 31, 2021

Common stock, $0.001 par value; 100,000,000 shares authorized at both March 31, 2022 and December 31, 2021; 18,597,522 and 17,831,875 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively

 

19

 

 

18

Additional paid-in capital

 

623,652

 

 

622,906

Accumulated deficit

 

(584,975)

 

 

(576,760)

Accumulated other comprehensive loss

(71)

(92)

Total stockholders’ equity

 

38,625

 

 

46,072

Total liabilities and stockholders’ equity

$

47,270

 

$

54,258

See accompanying notes to Condensed Consolidated Financial Statements.

3

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Operations

(unaudited)

(dollars in thousands, except per share amounts)

Three Months Ended March 31, 

2022

2021

Revenue

$

2,440

$

3,221

Cost of revenue

1,222

 

937

Gross profit

1,218

 

2,284

Operating expenses:

Sales and marketing

4,707

 

1,250

General and administrative

4,163

2,720

Research and development

748

 

571

Total operating expenses

9,618

 

4,541

Operating loss

(8,400)

 

(2,257)

Other expense (income), net:

Interest expense, net

(1)

599

Loss on extinguishment of debt, net

1,960

Other, net

(11)

(Gain) Loss on foreign currency exchange, net

(16)

33

Loss before income tax provision

(8,372)

(4,849)

Income tax (benefit) expense

(157)

25

Net loss

$

(8,215)

$

(4,874)

Net loss per share - basic and diluted:

Net loss per share - basic and diluted

$

(0.44)

$

(1.24)

Shares used to compute basic and diluted net loss per share

18,539,568

 

3,927,986

See accompanying notes to Condensed Consolidated Financial Statements.

4

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Comprehensive Loss

(unaudited)

(dollars in thousands)

Three Months Ended March 31, 

    

2022

2021

Net loss

$

(8,215)

$

(4,874)

Foreign currency translation adjustments

21

19

Other comprehensive income, net of tax

21

19

Comprehensive loss

$

(8,194)

$

(4,855)

See accompanying notes to Condensed Consolidated Financial Statements.

5

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Stockholders’ Equity

(unaudited)

(dollars in thousands)

Three Months Ended March 31, 2022

Series C Convertible

Additional

Accumulated Other

Total

Preferred Stock

Common Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

    

Shares

    

Amount

    

Shares

    

Amount

     

Capital

    

Deficit

    

Loss

     

Equity

Balance December 31, 2021

95,388

$

17,831,875

$

18

$

622,906

$

(576,760)

$

(92)

$

46,072

Net loss

(8,215)

(8,215)

Other comprehensive income, net of tax

21

21

Stock compensation

747

747

Issuance of stock from RSUs

765,647

1

(1)

Balance March 31, 2022

95,388

$

18,597,522

$

19

$

623,652

$

(584,975)

$

(71)

$

38,625

Three Months Ended March 31, 2021

Series B Convertible

Series C Convertible

Additional

Accumulated Other

Total

Preferred Stock

Preferred Stock

Common Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

Shares

    

Amount

    

Shares

    

Amount

    

Shares

    

Amount

     

Capital

    

Deficit

Loss

     

Equity

Balance December 31, 2020

3

$

95,388

$

1

3,486,253

$

3

$

529,432

$

(514,827)

$

(121)

$

14,488

Net loss

(4,874)

(4,874)

Other comprehensive income, net of tax

19

19

Stock-based compensation expense

101

101

Series G warrants issued

2,974

2,974

Balance March 31, 2021

3

$

95,388

$

1

3,486,253

$

3

$

532,507

$

(519,701)

$

(102)

$

12,708

See accompanying Notes to Condensed Consolidated Financial Statements.

6

Table of Contents

RESHAPE LIFESCIENCES INC.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(dollars in thousands)

Three Months Ended March 31, 

2022

2021

Cash flows from operating activities:

    

Net loss

$

(8,215)

$

(4,874)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation expense

 

94

 

7

Amortization of intangible assets

456

411

Noncash interest expense

43

Loss on extinguishment of debt, net

1,960

Stock-based compensation

747

101

Bad debt expense

26

27

Provision for inventory excess and obsolescence

78

1

Deferred income tax

(187)

Amortization of debt discount and deferred debt issuance costs

461

Other noncash items

(20)

17

Change in operating assets and liabilities, net of business combination:

 

 

Accounts and other receivables

 

379

 

(780)

Inventory

 

(1,073)

 

182

Prepaid expenses and other current assets

 

(137)

 

237

Accounts payable and accrued liabilities

420

296

Warranty liability

 

(25)

 

(50)

Other

 

79

 

Net cash used in operating activities

(7,378)

(1,961)

Cash flows from investing activities:

Capital expenditures

(7)

(119)

Proceeds from sale of capital assets

9

Cash provided by (used in) investing activities:

2

(119)

Cash flows from financing activities:

Proceeds from credit agreement

1,000

Net cash provided by financing activities

1,000

Effect of currency exchange rate changes on cash and cash equivalents

 

21

 

19

Net decrease in cash, cash equivalents and restricted cash

 

(7,355)

 

(1,061)

Cash, cash equivalents and restricted cash at beginning of period

22,815

3,007

Cash, cash equivalents and restricted cash at end of period

$

15,460

$

1,946

Supplemental disclosure:

Cash paid for income taxes

$

$

31

Noncash investing and financing activities:

Capital expenditures accruals

$

9

$

141

Fair value of warrants included as a component of loss on extinguishment of debt

2,974

See accompanying notes to Condensed Consolidated Financial Statements.

 

7

Table of Contents

ReShape Lifesciences Inc.

Notes to Condensed Consolidated Financial Statements

(dollars in thousands, except per share amounts; unaudited)

(1)  Basis of Presentation

The accompanying interim condensed consolidated financial statements and related disclosures of Reshape Lifesciences Inc. (the “Company” or “ReShape”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed on April 8, 2022. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted.

In the opinion of management, the interim consolidated condensed financial statements reflect all adjustments considered necessary for a fair statement of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

Reverse Stock Split and Merger Exchange Ratio

On June 15, 2021, and immediately prior to the closing of the merger of Obalon Therapeutics, Inc. and ReShape Lifesciences Inc., the Company effected a 1-for-3 reverse stock split. Accordingly, all share and per share amounts for the period presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split. No fractional shares were issued in connection with the reverse stock split. Unless otherwise noted, all references to shares of the Company’s common stock and per share amounts have also been adjusted to reflect the exchange ratio of 0.5367 Obalon shares for one ReShape share in connection with the merger.

Acquisition

The Company accounts for business combinations in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations. The results of businesses acquired in a business combination are included in the Company’s consolidated financial statements from the date of the acquisition. Purchase accounting results in assets and liabilities of an acquired business generally being recorded at their estimated fair values on the acquisition date. Any excess consideration over the fair value of assets acquired and liabilities assumed is recognized as goodwill. Transaction costs associated with business combinations are expensed as incurred and are included in general and administrative related costs in the consolidated statements of operations. The Company performs valuations of assets acquired and liabilities assumed and allocates the purchase price to its respective assets and liabilities. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates.

Upon completion of the business combination with Obalon on June 15, 2021, the transaction was treated as a “reverse acquisition” for financial accounting purposes. As a result of the controlling interest of the former shareholders of ReShape, for financial statement reporting and accounting purposes, ReShape was considered the acquirer under the acquisition method of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805-10-55. The reverse acquisition is deemed a capital transaction in substance whereas the historical assets and liabilities of Obalon before the business combination were replaced with the historical financial statements of ReShape in all future filings with the SEC.

Goodwill and Long-Lived Assets

Goodwill represents the excess of the cost of an acquired business over the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed in a business combination.

8

Table of Contents

Indefinite-lived intangible assets relate to in-process research and development ("IPR&D") acquired in business combinations. The estimated fair values of IPR&D projects acquired in a business combination which have not reached technological feasibility are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the projects. In accordance with guidance within FASB ASC 350 “Intangibles - Goodwill and Other,” goodwill and identifiable intangible assets with indefinite lives are not subject to amortization but must be evaluated for impairment.

We evaluate long-lived assets, including finite-lived intangible assets, for impairment by comparison of the carrying amounts to future net undiscounted cash flows expected to be generated by such assets when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Should an impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the asset’s fair value or estimates of future discounted cash flows.

For goodwill and indefinite-lived intangible assets, in-process research and development, we review for impairment annually and upon the occurrence of certain events as required by ASC Topic 350, “Intangibles — Goodwill and Other.” Goodwill and indefinite-lived intangible assets are tested at least annually for impairment and more frequently if events or changes in circumstances indicate that the asset might be impaired. We review goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If we are able to determine that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, we would conclude that goodwill is not impaired. If the carrying amount of a reporting unit is zero or negative, the second step of the impairment test is performed to measure the amount of impairment loss, if any, when it is more likely than not that a goodwill impairment exists. The Company did not record any impairment loss for goodwill or indefinite-lived intangible assets for the three months ended March 31, 2022 and 2021.

Fair Value of Financial Instruments

The carrying amounts of cash equivalents, accounts receivable, accounts payable and certain accrued and other liabilities approximate fair value due to their short-term maturities. Refer to Note 5 regarding the fair value of debt instruments and Note 9 regarding fair value measurements and inputs of warrants.

Net Loss Per Share

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

March 31, 

    

2022

    

2021

Stock options

 

833,974

 

23

Unvested restricted stock units

897,823

Convertible preferred stock

38

726

Warrants

 

6,952,335

 

8,164,319

Recent Accounting Pronouncements

There were no new accounting standards adopted by the Company in 2022.

New accounting standards not yet adopted are discussed below.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. In May 2019, the FASB issued ASU No. 2019-05, which amended the new standard by providing targeted transition relief. The new guidance replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. In November 2019, the FASB issued ASU No. 2019-11, which amended the new standard by providing

9

Table of Contents

additional clarification. This guidance is effective for the fiscal years and interim periods within those years beginning after December 15, 2022. The Company is currently evaluating the impact the guidance will have on its consolidated financial statements.

(2)  Liquidity and Management’s Plans

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company currently does not generate revenue sufficient to offset operating costs and anticipates such shortfalls to continue primarily due to the unpredictability of new variants of COVID-19, which may result in a slow-down of elective surgeries and restrictions in some locations. The Company believes that the actions presently being taken to further implement the Company’s business plan to expand sales with a direct to consumer marketing strategy will provide the opportunity for the Company to generate sufficient revenues to continue as a going concern. The Company believes in the viability of its business strategy and in its ability to raise additional funds, there can be no assurance to that effect. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues.

As of March 31, 2022, the Company had net working capital of approximately $15.5 million, primarily due to cash and cash equivalents and restricted cash of $15.5 million. The Company’s principal source of liquidity as of March 31, 2022, consisted of approximately $15.5 million of cash and cash equivalents and restricted cash, and $2.4 million of accounts receivable.

The Company’s anticipated operations include plans to (i) manufacture, and promote the sales and operations of the LAP-BAND® product line in order to expand sales domestically and internationally as well as to obtain cost savings synergies, (ii) introduce to the market place reshapecareTM and ReShape Marketplace as an extension of reshapecare (iii) continue clinical testing of the ReShape Vest, (iv) continue development of the Diabetes Bloc-Stim Neuromodulation, (v) seek opportunities to leverage our intellectual property portfolio and custom development services to provide third-party sales and licensing opportunities, and (vi) explore and capitalize on synergistic opportunities to expand our portfolio and offer future minimally invasive treatments and therapies in the obesity continuum of care, which includes the Obalon product line from the merger with Obalon that was completed on June 15, 2021. With the July 2021 financing transaction, the Company believes that it has the flexibility to manage the growth of its expenditures and operations.

COVID-19 Risk and Uncertainties and CARES Act

Since the first quarter of 2020, the COVID-19 pandemic has led to unprecedented restrictions on, distributions in, and other related impacts on business and personal activities, including a shift in healthcare priorities, which resulted in a significant decline in medical procedures in 2020 in the United States and foreign countries. Concerns remain regarding the pace of economic recovery due to virus resurgence, including new variants, across the globe as well as vaccine distribution and hesitancy. The United States and other foreign governments may continue existing measures or implement new restrictions and other requirements in light of the continuing spread of the COVID-19 pandemic. Due to the uncertainty caused by the COVID-19 pandemic, the full extent to which the pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, manufacturing, clinical trials, research and development costs, reserves and allowances, will depend on future developments that are highly uncertain and difficult to predict. These developments include, but are not limited to, the duration and spread of the outbreak (including new and more contagious variants of COVID-19), its severity, the actions to contain the virus or address its impact, the timing, distribution, public acceptance and efficacy of vaccines and other treatments, United States and foreign governments actions to respond to the reduction of global activity, and how quickly and to what extent normal economic and operating conditions can resume.

On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act established the Paycheck Protection Program (“PPP”) under which the Company received a PPP loan. On February 3, 2021, the Company submitted the application for PPP loan forgiveness according to the terms and conditions

10

Table of Contents

of the United States Small Business Administration’s (“SBA”) Loan Forgiveness Application (Revised June 24, 2002). On March 1, 2021, the Company received confirmation from the SBA that, the PPP Loan had been forgiven in full including all interest incurred. This may still be subject to audit by the SBA or relevant authorities, subject to terms and conditions of the PPP program. The Company was also able to benefit from the employee retention credit. For further details on the PPP loan and the employee retention credit, see Note 5 below.

(3)  Supplemental Balance Sheet Information

Components of selected captions in the condensed consolidated balance sheets consisted of the following:

Inventory:

March 31, 

December 31,

2022

    

2021

Raw materials

$

1,028

$

829

Sub-assemblies

1,231

682

Finished goods

 

1,739

 

1,492

Total inventory

$

3,998

$

3,003

Prepaid expenses and other current assets:

March 31, 

December 31,

2022

    

2021

Prepaid insurance

$

597

$

736

Prepaid advertising and marketing

947

698

Other current assets

215

188

Total prepaid expenses and other current assets

$

1,759

$

1,622

Accrued and other liabilities:

March 31, 

December 31,

2022

    

2021

Payroll and benefits

$

1,858

$

1,527

Customer deposits

596

549

Taxes

299

307

Accrued insurance premium

301

Accrued professional

396

300

Other liabilities

 

314

 

185

Total accrued and other liabilities

$

3,463

$

3,169

(4) Goodwill and Intangible Assets

Indefinite-lived intangible assets consist of IPR&D for the ReShape Vest recorded in connection with the Company’s 2017 acquisition of BarioSurg, Inc and developed technology recorded in connection with the Obalon acquisition. The Company’s finite-lived intangible assets consists of developed technology, trademarks and tradenames, and covenant not to compete. The estimated useful lives of these finite-lived intangible assets range from 3 to 10 years. The amortization expenses for the three months ended March 31, 2022 and 2021, were $0.5 million and $0.4 million, respectively.

11

Table of Contents

(5)  Debt

CARES Act

On April 24, 2020, the Company entered into a PPP Loan agreement with Silicon Valley Bank (“SVB”) under the PPP, which is part of the CARES Act administered by the United States Small Business Administration (“SBA”). As part of the application for these funds, the Company in good faith, has certified that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. This certification further requires the Company to take into account our current business activity and our ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. Under this program, the Company received proceeds of $1.0 million from the PPP Loan. In accordance with the requirements of the PPP, the Company used proceeds from the PPP Loan primarily for payroll costs, rent and utilities. The PPP Loan has a 1.00% interest rate per annum, matures on April 24, 2022 and is subject to the terms and conditions applicable to loans administered by the SBA under the PPP.

On February 23, 2021, the Company submitted the application for PPP loan forgiveness, in accordance with the terms and conditions of the SBA’s Loan Forgiveness Application (revised June 24, 2020). On March 1, 2021, the Company received confirmation from the SBA that the PPP Loan was forgiven in full including all interest incurred, which resulted in a gain on debt extinguishment of $1.0 million, during the three months ended March 31, 2021.

On December 27, 2020, the Taxpayer Certainty and Disaster Tax Relief Act of 2020 expanded certain benefits made available under the enhanced CARES Act, including modifying and extending the employee retention credit. As modified, the employee retention credit provides eligible employers with less than 500 employees a refundable tax credit against the employer’s share of social security taxes. The employee retention credit is equal to 70% of qualified wages paid to employees during calendar year 2021 for a maximum credit of $7,000 per employee for each calendar quarter through September 30, 2021. The Company recognized a $0.3 million employee retention credit during the three months ended March 31, 2021, which was offset against payroll tax expense.

Credit Agreement

On January 19, 2021, the Company and the Lender entered into an amendment to the credit agreement, originally entered into on March 25, 2020, that increased the amount available under delayed draw term loans by $1.0 million, and issued an additional 1,000,000 Series G Warrants. The Company evaluated the accounting related to the amendment and in conjunction with the warrants issued. Based on this analysis the Company determined the agreements are substantially different and extinguished the original credit agreement and recorded the amended credit agreement as a new debt at a fair value of $10.0 million. As a result, during the three months ended March 31, 2021, the Company recorded a debt discount of approximately $0.5 million and a $3.0 million loss on extinguishment of debt, which is comprised of the fair value of the warrants and unamortized debt issuance cost with the original credit agreement, offset by the debt discount. At March 31, 2021, there was approximately $0.1 million of unamortized debt discount. Pursuant to the amendment of the credit agreement, the maturity date of the loans are March 31, 2021 and the loans bear interest at LIBOR plus 2.5%.

On March 10, 2021, the Company and the Lender entered into an amendment to the credit agreement that extended the maturity date from March 31, 2021 to March 31, 2022. The Company has accounted for this amendment as a debt modification. The associated unamortized debt discount on the January 19, 2021 amendment of $0.1 million will be amortized as interest expense over the term of the amended credit agreement.

On June 28, 2021, the Company entered into a warrant exercise agreement with existing investors, including the Lender, to exercise certain outstanding warrants. For further details on this transaction see Note 9. The Company used some of the proceeds from this transaction to pay off the $10.5 million of debt outstanding under the credit agreement.

Asset Purchase Consideration Payable

The asset purchase consideration payable related to the Company’s December 2018 acquisition of the Lap-Band product line from Apollo Endosurgery, Inc. (“Apollo”), was initially recorded at net present value using a discount rate of 5.1%. The asset purchase consideration payable was originally secured by a first security interest in substantially all

12

Table of Contents

of the Company’s assets, but that security interest terminated in accordance with its terms in October 2019. At December 31, 2021, the Company had paid off the purchase consideration in full.

(6) Leases

The Company has noncancelable operating leases for office and warehouse space in San Clemente and Carlsbad, California, as well as noncancelable operating leases for certain office equipment that expire at various dates through 2022. The Company does not have any short-term leases or financing lease arrangements. The Company extended the San Clemente lease by twelve months with an end date of June 30, 2023 and extended the Carlsbad lease by three months with an end date of June 30, 2022. Certain of the Company’s equipment leases include variable lease payments that are adjusted periodically based on actual usage. Lease and non-lease components are accounted for separately.

Operating lease costs were $0.2 million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively. Variable lease costs were not material.

Supplemental information related to operating leases is as follows:

Balance sheet information at March 31, 2022

Operating lease ROU assets

$

524

Operating lease liabilities, current portion

$

441

Operating lease liabilities, long-term portion

86

Total operating lease liabilities

$

527

Cash flow information for the three months ended March 31, 2022

Cash paid for amounts included in the measurement of operating leases liabilities

$

200

Maturities of operating lease liabilities were as follows:

Twelve months ending March 31, 2022

    

    

2023

$

451

2024

87

Total lease payments

538

Less: imputed interest

11

Total lease liabilities

$

527

Weighted-average remaining lease term at end of period (in years)

1.0

Weighted-average discount rate at end of period

5.5

(7) Acquisition

On June 15, 2021, the Company completed the previously announced merger with Obalon, which was treated as a reverse acquisition for accounting purposes, for an aggregate purchase price of $30.6 million. This includes the issuance of 3,340,035 shares of common stock valued at $30.6 million at the closing market price on the day of merger and the cancellation of 2,680,301 shares of common stock. As a result of the controlling interest of the former shareholders of ReShape, for financial statement reporting and accounting purposes, ReShape was considered the acquirer under the acquisition method of accounting in accordance with ASC 805-10-55. The reverse acquisition is deemed a capital transaction in substance whereas the historical assets and liabilities of Obalon before the business combination were replaced with the historical financial statements of ReShape in all future filings with the SEC. There were no acquisition related costs recognized for the three months ended March 31, 2022 and 2021.

13

Table of Contents

Tangible and intangible assets acquired were recorded based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair value of the net assets acquired was recorded to goodwill. The following table summarizes the fair values of the assets acquired and liabilities assumed, primarily related to inventory, developed technology, goodwill (including the deductibility for tax purposes) and income tax related accruals:

Current assets

$

5,887

Property and equipment, net

796

Right-of-use assets

335

Other assets

1,898

Goodwill

21,566

Developed technology

2,730

Liabilities assumed

(2,650)

Total purchase price

30,562

Less: cash acquired

(5,207)

Total purchase price, net of cash acquired

$

25,355

As part of the warrant agreements there was a provision that would provide the holders, at their election, a cash payment based on a Black-Scholes valuation of the warrants in connection with certain fundamental transactions. This clause could be exercised by the holders for 30 days subsequent to the date of the transaction. The Company performed a preliminary valuation of the warrants and recorded a liability at the time of the merger of $2.0 million. During the third quarter of 2021, the Company completed its valuation of these warrants which resulted in a liability for the warrants of $1.3 million, a decrease of $0.7 million, which had a corresponding decrease to goodwill. The Company had one of the holders exercise the fundamental transaction option, and rather than paying cash both parties agreed on the Company issuing shares of common stock and new warrants to this investor. See Notes 8 and 9 below for additional details. As the 30 day period passed, the Company valued the remaining warrants using a Black-Scholes model with an exercise price ranging from $13.20 to $15.00 per share, a risk free rate of 0.44%, a volatility rate of 122.1% and a dividend rate of 0. This resulted in a total fair value of $0.9 million as of July 15, 2021, with the change in fair value being recognized as a component of warrant expense. The ending liability of $0.5 million was reclassified from a current liability to additional paid-in capital.

As of March 31, 2022, the Company is still finalizing the impact of acquisition accounting on deferred income taxes, which will be finalized when the pre-merger Obalon tax return is finalized.

Goodwill includes expected synergies and other benefits the Company believes will result from the acquisition. The developed technology has been capitalized at fair value as an intangible asset with an estimated life of 15 years. The developed technology was determined using the income approach. This approach determines fair value based on cash flow projections which are discounted to present value using a risk-adjusted rate of return, using nonrecurring Level 3 inputs. The discount rate used was 22.0%. For the year ended December 31, 2021, the Company fully impaired goodwill due to the decline in market capitalization.

(8)  Equity

Common Stock Issued Related to Restricted Stock Units

During the three months ended March 31, 2022, the Company issued 765,647 shares of common stock subject to vesting of the restricted stock units. For further details see Note 12. There were no shares issued during the three months ended March 31, 2021.

August 2021 Issuance of Common Stock for Services

On August 11, 2021, the Company entered into a consulting agreement in which the Company issued to the consultant 37,500 shares of restricted common stock for the consulting services in a private placement in reliance on Rule 4(a)(2) under the Securities Act of 1933, as amended (the “Securities Act”). The shares were deemed earned on the day of the agreement and became unrestricted six months after the agreement date which is when the contract term ends.

14

Table of Contents

July 2021 Exchange of Warrants for Common Stock

On July 16, 2021, the Company entered into an exchange agreement (the “Exchange Agreement”) with existing institutional investors to exchange certain outstanding warrants (the “Exchange Warrants”) for shares of common stock and new warrants to purchase common stock. The investors held common stock purchase warrants issued by the Company prior to the merger of Obalon and ReShape. The merger constituted a fundamental transaction under the Exchange Warrants and, as a result thereof, pursuant to the terms and conditions of the Exchange Warrants, the investors were entitled to a cash payment equal to the Black Scholes value of the Exchange Warrants, calculated in accordance with the terms of the Exchange Warrants (the “Black Scholes Payment”).

 

Subject to the terms and conditions set forth in the Exchange Agreement and, in reliance on Section 3(a)(9) of the Securities Act, in lieu of the Black Scholes Payment, the Company and the Investors agreed to exchange all of the Exchange Warrants for (a) a total of 504,861 shares of common stock, which was calculated by dividing the Black Scholes Payment by $4.038, which was equal to 95% of the closing market price of the Company’s common stock on The Nasdaq Capital Market on July 16, 2021 and (b) new warrants to purchase up to a total of 400,000 shares of common stock at an exercise price of $4.038 with a term of five years. For further details on the warrants see Note 9 below.

June 2021 Exercises of Warrants for Common Stock

On June 28, 2021, the Company entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 7.9 million shares of the Company’s common stock, of which 7.1 million shares were issued in July in accordance with the terms of the warrant exercise agreement. In consideration for the immediate exercise of the existing warrants for cash, the exercising holders received new unregistered warrants to purchase up to an aggregate of 5.9 million shares (equal to 75% of the shares of common stock issued in connection with the exercise) of the Company’s common stock (the “New Warrants”) in a private placement pursuant to Section 4(a)(2) of the Securities Act. The investors paid a cash purchase price for the New Warrants equal to $0.09375 per share of common stock underlying the New Warrants. In connection with the exercise, the Company also agreed to reduce the exercise price of certain of the existing warrants to $6.00, which is equal to the most recent closing price of the Company’s common stock on The Nasdaq Capital Market prior to the execution of the warrant exercise agreement. For further details on the warrants see Note 9 below.

The gross proceeds to the Company from the exercise and the sale of the New Warrants was approximately $45.5 million, prior to deducting placement agent fees and estimated offering expenses. The Company used approximately $10.8 million to pay off the credit agreement, including $10.5 million of debt and $0.3 million of accrued interest under its secured credit agreement dated March 25, 2020, as amended, see Note 5 above for further details. The Company intends to use the remainder of the net proceeds for working capital and general corporate purposes.

On June 18, 2021, the Company issued 100,000 shares of common stock to two healthcare focused institutional investors, totaling 200,000 shares of common stock and on June 21, 2021, the Company issued 130,445 and 57,229 shares of common stock to two healthcare focused institutional investors totaling 187,674 shares of common stock, as an exercise of pre-funded warrants issued in connection with the September 2019 private placement transactions. The Company received approximately $0.1 million in connection with the exercises

(9) Warrants

On July 16, 2021, the Company entered into an exchange agreement with an existing accredited investor to exchange certain outstanding warrants for shares of common stock and issued new warrants to purchase up to total of 400,000 shares of common stock at an exercise price of $4.038 per share with a term of 5 years. These new warrants were valued at $1.5 million using the fair value approach at the time of issuance. The fair value of the new warrants was determined using a Black Scholes option pricing model using a risk free rate of 0.79%, an expected term of five years, expected dividends of zero and expected volatility of 157.7%.

On June 28, 2021, the Company entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants. As part of this agreement the Company modified the Series E warrants issued September 23, 2019 from an exercise price of $10.64 per share to $6.00 per share, the Series G warrants issued on March 25, 2020 from an exercise price of $6.56 per share to $6.00 per share, the Series G warrants issued on December 17,

15

Table of Contents

2020 from an exercise price of $6.21 per share to $6.00 per share and the Series G warrants issued on January 21, 2021 from an exercise price of $6.21 per share to $6.00 per share. The Company issued a total of 7,929,384 shares of common stock in connection with this transaction and issued an additional 5,947,039 new warrants. These new warrants were valued at $18.5 million using the fair value approach at the time of issuance. The fair value the new warrants was determined using a Black Scholes option pricing model using a risk free rate of 0.898%, an expected term of five years, expected dividends of zero and expected volatility of 97.6%.

On January 19, 2021, the Company issued 1,000,000 Series G Warrants, pre-merger, which were adjusted by the exchange ratio in the merger, to an institutional investor in connection with an amendment to the credit agreement. The Series G Warrants were valued at $3.0 million using the fair value approach at the time of issuance and was recorded as a component of the loss on extinguishment of debt during the three months ended March 31, 2021. See Note 5 above for details. The fair value of the Series G Warrants was determined using a Black Scholes option pricing model using a risk free rate of 0.45%, an expected term of five years; expected dividends of zero and expected volatility of 97.1%.

(10) Revenue Disaggregation and Operating Segments

The Company conducts operations worldwide and has sales in the following regions: United States, Australia, Europe and Rest of World. For the three months ended March 31, 2022 and 2021, the Company primarily only sold the Lap-Band system. The following table presents the Company’s revenue disaggregated by geography:

Three Months Ended

March 31, 

    

2022

    

2021

United States

$

1,844

$

2,520

Australia

181

293

Europe

414

379

Rest of world

1

29

Total revenue

$

2,440

$

3,221

Operating Segments

The Company conducts operations worldwide and is managed in the following geographical regions: United States, Australia, Europe and the Rest of World (primarily in the Middle East). All regions sell the Lap-Band system, which consisted of nearly all our revenue and gross profit for the three months ended March 31, 2022 and 2021. During the three months ended March 31, 2022 and 2021, there was minimal revenue for reshapecare. There was no revenue or gross profit recorded for the ReShape Vest or Diabetes Bloc-Stim Neuromodulation for the three months ended March 31, 2022 and 2021 as these two products are still in the development stage. There was also no revenue recorded for the recently acquired Obalon line.

(11) Income Taxes

During the three months ended March 31, 2022, a $0.2 million tax benefit was recorded primarily due to a reduction in the valuation allowance related to an impairment of indefinite lived assets partially offset by state and foreign taxes. During the three months ended March 31, 2021, a $25 thousand tax expense was recorded, primarily due to U.S. state minimum taxes and projected income in Australia and the Netherlands. The income tax provisions for the three months ended March 31, 2022 and year ended December 31, 2021, were calculated using the discrete year-to-date method. The effective tax rate differs from the statutory tax rate of 21% primarily due to the existence of valuation allowances against net deferred tax assets and current liabilities resulting from the estimated state income tax liabilities and foreign tax liability.

In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Based on the level of historical losses, projections of losses in future periods and potential limitations pursuant to changes in ownership under Internal Revenue Code Section 382, the Company provided a valuation allowance at both March 31, 2022 and December 31, 2021.

16

Table of Contents

(12)  Stock-based Compensation

Stock-based compensation expense related to stock options and RSUs issued under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan (the “Plan”) for the three months ended March 31, 2022 and 2021 were as follows:

Three Months Ended

March 31, 

2022

2021

Sales and marketing

$

104

$

General and administrative

570

101

Research and development

73

Total stock-based compensation expense

$

747

$

101

Stock Options

A summary of the status of the Company’s stock options as of March 31, 2022 and changes during the three months ended March 31, 2022 are as follows:

    

Weighted

Weighted

Average

Aggregate

Average

Remaining

Intrinsic

    

Exercise Price

Contractual

Value

Shares

Per Share

Life (years)

(in thousands)

Outstanding at December 31, 2021

 

885,039

7.97

$

Options granted

 

Options exercised

 

Options cancelled

 

(51,065)

3.62

Outstanding at March 31, 2022

 

833,974

8.23

8.9

$

Exercisable at March 31, 2022

612,410

9.90

8.7

Vested and expected to vest at March 31, 2022

833,974

8.23

8.9

There was no intrinsic value of the outstanding stock options at March 31, 2022. The unrecognized share-based expense at March 31, 2022 was $0.8 million and will be recognized over a weighted average period of 2.2 years.

Stock option awards outstanding under the Company’s incentive plans have been granted at exercise prices that are equal to the market value of its common stock on the date of grant. Such options generally vest over a period of four years and expire at ten years after the grant date. The Company recognized compensation expense ratably over the vesting period. The Company uses a Black-Scholes option-pricing model to estimate the fair value of stock options granted, which requires the input of both subjective and objective assumptions as follows:

Expected Term – The estimate of expected term is based on the historical exercise behavior of grantees, as well as the contractual life of the options granted.

Expected Volatility – The expected volatility factor is based on the volatility of the Company’s common stock for a period equal to the term of the stock options.

Risk-free Interest Rate – The risk-free interest rate is determined using the implied yield for a traded zero-coupon U.S. Treasury bond with a term equal to the expected term of the stock options.

Expected Dividend Yield – The expected dividend yield is based on the Company’s historical practice of paying dividends on its common stock.

17

Table of Contents

Restricted Stock Units

During the three months ended March 31, 2022, the Company did not grant or cancel any RSUs.

A summary of the Company’s unvested RSUs award activity for the three months ended March 31, 2022, were as follows:

Weighted

Average

    

Grant Date

Shares

Fair Value

Unvested RSUs at December 31, 2021

 

1,711,318

$

Granted

 

4.36

Vested (1)

 

(813,495)

4.36

Cancelled/Forfeited

 

Non-vested RSUs at March 31, 2022

 

897,823

4.36

(1)At March 31, 2022, there were 47,848 shares of common stock related to RSU awards that had vested and the shares were not distributed to the participants until April of 2022. The Company recorded a liability to account for these shares and reversed the liability once the shares were issued to the participants.

The fair value of each RSU is the closing stock price on the Nasdaq of the Company’s common stock on the date of grant. Upon vesting, a portion of the RSU award may be withheld to satisfy the statutory income tax withholding obligation. The remaining RSUs will be settled in shares of the Company’s common stock after the vesting period. The unrecognized compensation cost related to the RSUs at March 31, 2022 was $3.9 million and expected to be recognized over a period of 1.8 years.

(13)  Commitment and Contingencies

Litigation

On August 6, 2021, Cowen and Company, LLC filed a complaint against ReShape, as successor in interest to Obalon Therapeutics, in the Supreme Court of the State of New York based on an alleged breach of contract arising out of Cowen’s prior engagement as Obalon’s financial advisor. The complaint alleges that Cowen is entitled to be paid a $1.35 million fee in connection with ReShape’s merger with Obalon under the terms of Cowen’s engagement agreement with Obalon. The complaint also seeks reimbursement of Cowen’s attorneys’ fees and interest in connection with its claim. The Company is unable to predict the ultimate outcome of this matter; therefore, no amounts have been accrued. The Company intends to vigorously defend this matter.

On August 18, 2021, H.C. Wainwright & Co., LLC filed a complaint against ReShape in the Supreme Court of the State of New York based on an alleged breach of contract arising out of Wainwright’s prior engagement by ReShape in connection with certain capital raising transactions by ReShape. The complaint alleges that Wainwright is entitled to be paid a fee in connection with ReShape’s capital raising transaction under the warrant exercise agreement that ReShape entered into on June 28, 2021. Wainwright alleges that its June and September 2019 engagement agreements with ReShape require ReShape to pay Wainwright a cash fee equal to 8.0% of the gross proceeds that ReShape received from the exercise of warrants issued pursuant to those engagement agreements, including warrants that were exercised in the June 2021 transaction. The complaint also seeks reimbursement of Wainwright’s attorneys’ fees and interest in connection with its claim. The Company is unable to predict the ultimate outcome of this matter or estimate a range of possible exposure; therefore, no amounts have been accrued. The Company intends to vigorously defend this matter.

Product Liability Claims

The Company is exposed to product liability claims that are inherent in the testing, production, marketing and sale of medical devices. Management believes any losses that may occur from these matters are adequately covered by insurance, and the ultimate outcome of these matters will not have a material effect on the Company’s financial position or results of operations. The Company is not currently a party to any product liability litigation and is not aware of any pending or threatened product liability litigation that is reasonably possible to have a material adverse effect on the Company’s business, operating results or financial condition.

18

Table of Contents

ITEM  2.       MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 

The following discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. 

Except for the historical information contained herein, the matters discussed in this "Management's Discussion and Analysis of Financial Condition and Results of Operations," are forward-looking statements that involve risks and uncertainties. In some cases, these statements may be identified by terminology such as "may," "will," "should," "expects," "could," "intends," "might," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of such terms and other comparable terminology. These statements involve known and unknown risks and uncertainties that may cause our results, level of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Factors that may cause or contribute to such differences include, among others, those discussed in the "Risk Factors" section included in Item 1A of our most recent Annual Report on Form 10-K. 

Except as may be required by law, we undertake no obligation to update any forward-looking statement to reflect events after the date of this report. 

Overview

We are the premier global weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and associated metabolic disease. Our primary operations are in the following geographical areas: United States, Australia and certain European and Middle Eastern countries. Our current portfolio includes the Lap-Band Adjustable Gastric Banding System, the reshapecare virtual health coaching program, the ReShape Marketplace, the Obalon Balloon System, the ReShape Vest, an investigational device to help treat more patients with obesity, and the Diabetes Bloc-Stim Neuromodulation device, a technology under development as a new treatment for type 2 diabetes mellitus. There has been no revenue recorded for the ReShape Vest or the Diabetes Bloc-Stim Neuromodulation as these products are still in the development stage. We continue to explore the compliance requirements, manufacturing viability and quality system controls necessary for re-introducing the Obalon Balloon System.

Recent Developments

On February 16, 2022, the Company renewed the office space lease in San Clemente, California for one year. This lease renewal will commence on July 1, 2022, and end on June 30, 2023.

19

Table of Contents

Results of Operations

The following table sets forth certain data from our unaudited consolidated statements of operations expressed as percentages of revenue (in thousands):

Three Months Ended March 31, 

2022

2021

Revenue

$

2,440

100.0

%

$

3,221

100.0

%

Cost of goods sold

1,222

50.0

%

937

29.1

%

Gross profit

1,218

50.0

%

2,284

70.9

%

Operating expenses:

Sales and marketing

4,707

192.9

%

1,250

38.8

%

General and administrative

4,163

170.6

%

2,720

84.5

%

Research and development

748

30.7

%

571

17.7

%

Total operating expenses

9,618

394.2

%

4,541

141.0

%

Operating loss

(8,400)

(344.2)

%

(2,257)

(70.1)

%

Other expense (income), net:

Interest expense, net

(1)

%

599

18.6

%

Loss on extinguishment of debt, net

%

1,960

60.9

%

Other, net

(11)

(0.5)

%

%

Gain on foreign currency

(16)

(0.7)

%

33

1.0

%

Loss before income tax provision

(8,372)

(343.0)

%

(4,849)

(150.5)

%

Income tax benefit

(157)

(6.4)

%

25

0.8

%

Net loss

$

(8,215)

(336.6)

%

$

(4,874)

(151.3)

%

Non-GAAP Disclosures

In addition to the financial information prepared in conformity with GAAP, we provide certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company’s ongoing core operating performance than their GAAP equivalents.

Management believes that the presentation of this non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results across a broad spectrum of companies with varying capital structures, compensation strategies, derivative instruments, and amortization methods, which provides a more complete understanding of our financial performance, competitive position, and prospects for the future. However, the non-GAAP financial measures presented in the Form 10-Q have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

Adjusted EBITDA

Management uses adjusted EBITDA in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation, and other one-time costs.

20

Table of Contents

The following table contains a reconciliation of non-GAAP net loss to GAAP net loss attributable to common stockholders for the three months ended March 31, 2022 and 2021 (in thousands):

Three Months Ended March 31, 

2022

2021

GAAP net loss

$

(8,215)

$

(4,874)

Adjustments:

Interest expense, net

(1)

599

Income tax expense (benefit)

(157)

25

Depreciation and amortization

550

418

Stock-based compensation expense

747

101

Loss on extinguishment of debt, net

1,960

Non-GAAP loss

$

(7,076)

$

(1,771)

Comparison of Results of Operations

Three months ended March 31, 2022 and March 31, 2021

Revenue: The following table summarizes our unaudited revenue by geographic location based on the location of customers for the three months ended March 31, 2022 and 2021, as well as the percentage of each location to total revenue and the amount of change and percentage of change (dollars in thousands):

Three Months Ended March 31, 

Amount

Percentage

2022

2021

Change

Change

United States

$

1,844

75.6

%

$

2,520

78.2

%

$

(676)

(26.8)

%

Australia

181

7.4

%

293

9.1

%

(112)

(38.2)

%

Europe

414

17.0

%

379

11.8

%

35

9.2

%

Rest of world

1

%

29

0.9

%

(28)

(96.6)

%

Total revenue

$

2,440

100.0

%

$

3,221

100.0

%

$

(781)

(24.2)

%

Revenue totaled $2.4 million for the three months ended March 31, 2022, which represents a contraction of 24.2%, or $0.8 million for the same period in 2021. The primary reason, is due to the emergence in late 2021 of the fast-spreading omicron variant of COVID-19 resulting in a significant rise in global cases causing a significant number of bariatric centers to close December 2021 through February 2022. During March 2022, we experienced a significant increase in revenue compared to January and February 2022, as the omicron variant began to subside. Our expectation is revenue will continue to increase through the remainder of 2022, as we have witnessed a significant growth in our web traffic and doctor consultations, attributable to the direct to consumer marketing campaign we launched during the fourth quarter of 2021.

Cost of Goods Sold and Gross Profit: The following table summarizes our unaudited cost of revenue and gross profit for the three months ended March 31, 2022 and 2021, as well as the percentage compared to total revenue and amount of change and percentage of change (dollars in thousands):

Three Months Ended March 31, 

Amount

Percentage

2022

2021

Change

Change

Revenue

$

2,440

100.0

%

$

3,221

100.0

%

$

(781)

(24.2)

%

Cost of goods sold

1,222

50.0

%

937

29.1

%

285

30.4

%

Gross profit

$

1,218

50.0

%

$

2,284

70.9

%

$

(1,066)

(46.7)

%

Gross Profit. Gross profit for the three months ended March 31, 2022, was $1.2 million, compared to $2.3 million for the same period in 2021, a decrease of $1.1 million. Gross profit as a percentage of total revenue for the three months ended March 31, 2022, was 50.0% compared to 70.9% for the same period in 2021. The decrease in gross profit margin is primarily due to a reduction in revenue compiled with department expenses, which are more fixed in nature, such as payroll related expenses, consulting fees, depreciation, along with increased freight costs.

21

Table of Contents

Operating Expenses: The following table summarizes our unaudited operating expenses for the three months ended March 31, 2022, and 2021, as well as the percentage of total revenue and the amount of change and percentage of change (dollars in thousands):

Three Months Ended March 31, 

Amount

Percentage

2022

2021

Change

Change

Sales and marketing

$

4,707

192.9

%

$

1,250

38.8

%

$

3,457

276.6

%

General and administrative

4,163

170.6

%

2,720

84.5

%

1,443

53.1

%

Research and development

748

30.7

%

571

17.7

%

177

31.0

%

Total operating expenses

$

9,618

394.2

%

$

4,541

141.0

%

$

5,077

111.8

%

Sales and Marketing Expense. Sales and marketing expenses for the three months ended March 31, 2022, increased by $3.5 million, or 276.6%, to $4.7 million, compared to $1.2 million for the same period in 2021. The increase is primarily due to an increase in advertising and marketing costs of $2.8 million, as the Company launched its direct to consumer marketing campaign during the fourth quarter of 2021, and expanded this campaign during the first quarter of 2022, increasing its presence within video, print and social media platforms. In addition, we had an increase in payroll related expenses of $0.5 million, as we continue to strengthen our commercial organization and have hired a senior VP of Commercial Operations, as well as additional sales personnel. We also had an increase in stock-based compensation expense of $0.1 million, during the third quarter of 2021, as the Company issued both RSUs and stock options, which were the first equity grants issued since 2018. The Company had an increase of travel expenses of $0.1 million, primarily due to relaxing of COVID-19 restrictions.

General and Administrative Expense. General and administrative expenses for the three months ended March 31, 2022, increased by $1.4 million, or 53.1%, to $4.1 million, compared to $2.7 million for the same period in 2021. The increase is primarily due to an increase of $0.5 million in stock-based compensation expense related to the issuance during the third quarter of 2021 of both RSUs and stock options. In addition, the Company had an increase in payroll related expenses of $0.3 million, due primarily to increases in salaries. The Company had an increase in legal and patent fees of $0.2 million, primarily related to a legal settlement during the first quarter of 2022. There was an increase in audit, consulting, legal and other professional services of $0.1 million. The Company had increases of $0.2 million and $0.1 million, in rent and facilities, and insurance respectively, directly attributable to the merger with Obalon.

Research and Development Expense. Research and development expenses for the three months ended March 31, 2022, increased by $0.2 million, or 31.0%, to $0.8 million, compared to $0.6 million for the same period in 2021. The increase is due to an increase of $0.1 million in stock-based compensation expense related to the issuance during the third quarter of 2021 of both RSUs and stock options. In addition, the Company had an increase of $0.1 million in payroll related expenses.

Net Interest Expense. Net interest expense for the three months end March 31, 2022, decreased by $0.6 million to $1 thousand compared to $0.6 million for the same period in 2021. The reason for the decrease is due to the Company paying off all of its debt during the second quarter of 2021.

(Gain) Loss on Foreign Currency. The Company had a gain on foreign currency of $16 thousand for the three months ended March 31, 2022, compared to a loss of $33 thousand for the same period in 2021.

Income Tax (Benefit) Expense. The Company had an income tax benefit of $0.2 million for the three months ended March 31, 2022, primarily due to a reduction in the valuation allowance related to an impairment of indefinite lived assets. An income tax expense of $25 thousand was recorded for the three months ended March 31, 2021, primarily related to projected income in Australia and Netherlands.

Liquidity and Capital Resources

Our sources of cash liquidity consist of cash and cash equivalents and cash from operations. We believe that these sources are sufficient to fund the current requirements of working capital, capital expenditures, and other financial commitments for the next twelve months. As of March 31, 2022, we had $15.5 million of cash and cash equivalents, which includes $50 thousand of restricted cash.

22

Table of Contents

The Company is also evaluating further funding options, including seeking additional equity or debt financing to support the expansion of the Lap-Band system, reshapecare, and the continued development of the ReShape Vest and the ReShape Diabetes Bloc-Stim Neuromodulation; and the re-introduction of the Obalon Balloon System and other strategic market opportunities.

The following table summarizes our change in cash and cash equivalents and restricted cash (in thousands):

Three Months Ended

March 31, 

2022

    

2021

Net cash used in operating activities

$

(7,378)

$

(1,961)

Net cash received (used) in investing activates

2

(119)

Net cash provided in financing activities